Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ronald De Wit, Thomas Powles, Daniel E. Castellano, Andrea Necchi, Jae-Lyun Lee, Michiel Simon Van Der Heijden, Nobuaki Matsubara, Aristotelis Bamias, Aude Flechon, Cora N. Sternberg, Alexandra Drakaki, Evan Y. Yu, Oday Hamid, Annamaria Zimmermann, Ling Gao, Amanda Long, Richard A. Walgren, Katherine M. Bell-McGuinn, Daniel Peter Petrylak
Institutions: Erasmus MC Cancer Institute, Queen Mary University of London, Barts Cancer Institute, Hospital Universitario 12 De Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Asan Medical Center, University of Ulsan, The Netherlands Cancer Institute, National Cancer Center Hospital East, National and Kapodistrian University of Athens, Centre Léon Bérard, Azienda Ospedaliera San Camillo-Forlanini, University of California, Los Angeles, Seattle Cancer Care Alliance, Eli Lilly (United States), Memorial Sloan Kettering Cancer Center, Yale University
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891075571